Aclarion Reports Q3 Growth and Trial Progress
The Broomfield-based company highlighted an 85% year-over-year increase in scan volume during the third quarter of 2026.
Updated on Oct. 20, 2026 in Healthcare
Live Poll
Do you trust that health tech companies prioritize long-term clinical patient outcomes over short-term financial targets?
Aclarion released a shareholder letter detailing significant growth in scan volume and updates on its ongoing clinical trials. The company currently holds $14.2 million in cash, which is expected to support operations through the second half of 2027.
Why it matters
The company is refining enrollment criteria for its CLARITY trial to speed up recruitment and improve real-world data applicability. This strategy supports Aclarion's goal of securing reimbursement for its diagnostic technology in both the United Kingdom and the United States.
Aclarion recorded 85% year-over-year scan volume growth in the third quarter of 2026 and 117% growth for the nine months ended September 30. The company currently maintains $14.2 million in cash while operating the CLARITY trial across 11 clinical sites.
The players
Aclarion
Aclarion is a healthcare technology company headquartered in Broomfield that focuses on diagnostic innovations for spinal conditions.
The details
Aclarion utilizes Nociscan technology to extract chemical biomarkers from MRI data for spinal diagnostics. Peer-reviewed data published in the European Spine Journal recently validated the use of this MRS technology as a potential alternative to invasive provocative discography.
Timeline
September 30, 2026, marked the end of the company's third fiscal quarter.
October 20, 2026, was the date of the CEO shareholder letter publication.
Year-end 2026 is when the company anticipates an update on CLARITY trial enrollment.
The second half of 2027 is the projected end of the company's current cash runway.
Market Landscape
The progress of the CLARITY clinical trial mirrors broader industry trends toward evidence-based reimbursement strategies in spine care. Aclarion is positioning its diagnostic biomarker technology to compete with established legacy procedures in both U.S. and European markets.
Patients and healthcare providers may see increased availability of non-invasive diagnostic options as Aclarion pursues reimbursement pathways. The company's expansion into new clinical sites aims to normalize the use of MRI-based biomarker extraction for spinal assessments.
The takeaway
Aclarion continues to focus on validating its MRI-based technology as a standard clinical alternative to traditional discography. Investors and patients should monitor the upcoming 2026 year-end update for clearer timelines on trial data and regulatory goals.
What happens next
Aclarion plans to provide a formal update regarding enrollment progress and expected timelines for the CLARITY trial results by the end of 2026.
Further reading
Learn more about local sector developments in Healthcare.
Live Poll
Do you trust that health tech companies prioritize long-term clinical patient outcomes over short-term financial targets?
